| Benjamin Leishman, DO | |
|
820 E 17th St, Cheyenne, WY 82001-4714 | |
| (307) 632-2434 | |
| Not Available |
| Full Name | Benjamin Leishman |
|---|---|
| Gender | Male |
| Speciality | Osteopathic Manipulative Medicine |
| Experience | 8 Years |
| Location | 820 E 17th St, Cheyenne, Wyoming |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063862977 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Brio Idaho Home Health Llc | Idaho falls, ID | Home health agency |
| Mountain View Hospital | Idaho falls, ID | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mountain View Hospital Llc | 4486562774 | 176 |
News Archive
Usually starting as a blemish, skin cancer can quickly develop and spread to other parts of the body. The deadliest form of skin cancer, melanoma proliferates rapidly through the lymph nodes, affecting important internal organs. The disease can be variable, wherein some cancer cells never metastasize to the blood and lymph nodes and throughout the body, while others, tend to metastasize.
A simple-to-use risk score can identify low-risk patients following a severe heart attack (STEMI) and may provide an opportunity to employ early discharge strategies to reduce length of hospital stay and save hospital costs without compromising the safety of the patient, based on a study presented by the Minneapolis Heart Institute Foundation on Oct. 23 at the 2012 Transcatheter Cardiovascular Therapeutics (TCT) conference.
Charles J. Dimitroff, MS, PhD and colleagues in the Dimitroff Lab at Brigham and Women's Hospital, have developed a fluorinated analog of glucosamine, which, in a recent study, has been shown to block the synthesis of key carbohydrate structures linked to skin inflammation and cancer progression. These findings appear in the April 14, 2011, issue of the Journal of Biological Chemistry.
Neuralstem, Inc. (NYSE Amex: CUR) today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to commence a Phase I trial to treat Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease) with its spinal cord stem cells.
Heraeus Kulzer, LLC, the worldwide leader in dental esthetics, announced today that its iBOND Self Etch bonding agent received the maximum possible "5-plus" rating from THE DENTAL ADVISOR. The iBOND Self Etch bottle kit was evaluated by 26 consultants in 648 uses and received a very impressive 96% clinical rating.
› Verified 2 days ago
| Entity Name | Mountain View Hospital Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669462362 PECOS PAC ID: 4486562774 Enrollment ID: O20040527001343 |
News Archive
Usually starting as a blemish, skin cancer can quickly develop and spread to other parts of the body. The deadliest form of skin cancer, melanoma proliferates rapidly through the lymph nodes, affecting important internal organs. The disease can be variable, wherein some cancer cells never metastasize to the blood and lymph nodes and throughout the body, while others, tend to metastasize.
A simple-to-use risk score can identify low-risk patients following a severe heart attack (STEMI) and may provide an opportunity to employ early discharge strategies to reduce length of hospital stay and save hospital costs without compromising the safety of the patient, based on a study presented by the Minneapolis Heart Institute Foundation on Oct. 23 at the 2012 Transcatheter Cardiovascular Therapeutics (TCT) conference.
Charles J. Dimitroff, MS, PhD and colleagues in the Dimitroff Lab at Brigham and Women's Hospital, have developed a fluorinated analog of glucosamine, which, in a recent study, has been shown to block the synthesis of key carbohydrate structures linked to skin inflammation and cancer progression. These findings appear in the April 14, 2011, issue of the Journal of Biological Chemistry.
Neuralstem, Inc. (NYSE Amex: CUR) today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to commence a Phase I trial to treat Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease) with its spinal cord stem cells.
Heraeus Kulzer, LLC, the worldwide leader in dental esthetics, announced today that its iBOND Self Etch bonding agent received the maximum possible "5-plus" rating from THE DENTAL ADVISOR. The iBOND Self Etch bottle kit was evaluated by 26 consultants in 648 uses and received a very impressive 96% clinical rating.
› Verified 2 days ago
| Entity Name | Community Care West Side Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295009785 PECOS PAC ID: 3678738218 Enrollment ID: O20120703000554 |
News Archive
Usually starting as a blemish, skin cancer can quickly develop and spread to other parts of the body. The deadliest form of skin cancer, melanoma proliferates rapidly through the lymph nodes, affecting important internal organs. The disease can be variable, wherein some cancer cells never metastasize to the blood and lymph nodes and throughout the body, while others, tend to metastasize.
A simple-to-use risk score can identify low-risk patients following a severe heart attack (STEMI) and may provide an opportunity to employ early discharge strategies to reduce length of hospital stay and save hospital costs without compromising the safety of the patient, based on a study presented by the Minneapolis Heart Institute Foundation on Oct. 23 at the 2012 Transcatheter Cardiovascular Therapeutics (TCT) conference.
Charles J. Dimitroff, MS, PhD and colleagues in the Dimitroff Lab at Brigham and Women's Hospital, have developed a fluorinated analog of glucosamine, which, in a recent study, has been shown to block the synthesis of key carbohydrate structures linked to skin inflammation and cancer progression. These findings appear in the April 14, 2011, issue of the Journal of Biological Chemistry.
Neuralstem, Inc. (NYSE Amex: CUR) today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to commence a Phase I trial to treat Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease) with its spinal cord stem cells.
Heraeus Kulzer, LLC, the worldwide leader in dental esthetics, announced today that its iBOND Self Etch bonding agent received the maximum possible "5-plus" rating from THE DENTAL ADVISOR. The iBOND Self Etch bottle kit was evaluated by 26 consultants in 648 uses and received a very impressive 96% clinical rating.
› Verified 2 days ago
| Entity Name | Cc Pocatello Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538517156 PECOS PAC ID: 8527353176 Enrollment ID: O20160822003018 |
News Archive
Usually starting as a blemish, skin cancer can quickly develop and spread to other parts of the body. The deadliest form of skin cancer, melanoma proliferates rapidly through the lymph nodes, affecting important internal organs. The disease can be variable, wherein some cancer cells never metastasize to the blood and lymph nodes and throughout the body, while others, tend to metastasize.
A simple-to-use risk score can identify low-risk patients following a severe heart attack (STEMI) and may provide an opportunity to employ early discharge strategies to reduce length of hospital stay and save hospital costs without compromising the safety of the patient, based on a study presented by the Minneapolis Heart Institute Foundation on Oct. 23 at the 2012 Transcatheter Cardiovascular Therapeutics (TCT) conference.
Charles J. Dimitroff, MS, PhD and colleagues in the Dimitroff Lab at Brigham and Women's Hospital, have developed a fluorinated analog of glucosamine, which, in a recent study, has been shown to block the synthesis of key carbohydrate structures linked to skin inflammation and cancer progression. These findings appear in the April 14, 2011, issue of the Journal of Biological Chemistry.
Neuralstem, Inc. (NYSE Amex: CUR) today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to commence a Phase I trial to treat Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease) with its spinal cord stem cells.
Heraeus Kulzer, LLC, the worldwide leader in dental esthetics, announced today that its iBOND Self Etch bonding agent received the maximum possible "5-plus" rating from THE DENTAL ADVISOR. The iBOND Self Etch bottle kit was evaluated by 26 consultants in 648 uses and received a very impressive 96% clinical rating.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Benjamin Leishman, DO 820 E 17th St, Cheyenne, WY 82001-4714 Ph: (307) 632-2434 | Benjamin Leishman, DO 820 E 17th St, Cheyenne, WY 82001-4714 Ph: (307) 632-2434 |
News Archive
Usually starting as a blemish, skin cancer can quickly develop and spread to other parts of the body. The deadliest form of skin cancer, melanoma proliferates rapidly through the lymph nodes, affecting important internal organs. The disease can be variable, wherein some cancer cells never metastasize to the blood and lymph nodes and throughout the body, while others, tend to metastasize.
A simple-to-use risk score can identify low-risk patients following a severe heart attack (STEMI) and may provide an opportunity to employ early discharge strategies to reduce length of hospital stay and save hospital costs without compromising the safety of the patient, based on a study presented by the Minneapolis Heart Institute Foundation on Oct. 23 at the 2012 Transcatheter Cardiovascular Therapeutics (TCT) conference.
Charles J. Dimitroff, MS, PhD and colleagues in the Dimitroff Lab at Brigham and Women's Hospital, have developed a fluorinated analog of glucosamine, which, in a recent study, has been shown to block the synthesis of key carbohydrate structures linked to skin inflammation and cancer progression. These findings appear in the April 14, 2011, issue of the Journal of Biological Chemistry.
Neuralstem, Inc. (NYSE Amex: CUR) today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to commence a Phase I trial to treat Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease) with its spinal cord stem cells.
Heraeus Kulzer, LLC, the worldwide leader in dental esthetics, announced today that its iBOND Self Etch bonding agent received the maximum possible "5-plus" rating from THE DENTAL ADVISOR. The iBOND Self Etch bottle kit was evaluated by 26 consultants in 648 uses and received a very impressive 96% clinical rating.
› Verified 2 days ago
Dr. Kristine K Van Kirk, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 6015 Sycamore Rd, Cheyenne, WY 82009 Phone: 307-823-2968 | |
Dr. Christian Alexander Flanders, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 820 E 17th St, Cheyenne, WY 82001 Phone: 307-632-2434 Fax: 307-634-3510 | |
Dr. Bradley Mohar, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 214 E 23rd St, Cheyenne, WY 82001 Phone: 307-634-2273 | |
Dr. Douglas W Edgren, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1331 Prairie Ave Ste 1, Cheyenne, WY 82009 Phone: 307-632-0728 | |
Zachary Dale Herman, Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 820 E 17th St, Cheyenne, WY 82001 Phone: 307-632-2434 Fax: 307-635-3510 | |
Margaret Ann Lembitz, NP Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 3229 E Pershing Blvd, Cheyenne, WY 82001 Phone: 307-363-2054 Fax: 307-227-6817 |